For solid tumors, which often exhibit poor CAR-T cell suitability owing to the unfavorable tumor microenvironment for T cells, limited T-cell infiltration, and heterogeneous tumor cell immune phenotypes, a bispecific CAR-T approach targeting epithelial cell adhesion molecule (EpCAM) and intercellular adhesion molecule 1 (ICAM-1) has been developed and explored with the aim of enhancing and sustaining the antitumor responses by addressing multiple challenges inherent to the treatment of solid tumors [64]. The gene discussed is EPCAM; the disease is neoplasm.